Neuropediatrics 2025; 56(S 01): S1-S24
DOI: 10.1055/s-0045-1812123
Long-Term Safety of Givinostat in Patients with Duchenne Muscular Dystrophy: Results
from an Open-Label Extension Study
Authors
-
K. Gilling
1
ITF Pharma GmbH, Munich, Germany
-
J. Brandsema
2
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
-
G. Acsadi
3
Connecticut Children's, Hartford, Connecticut, United States
-
N. Coceani
4
Italfarmaco SpA., Milan, Italy
-
F. Alessi
4
Italfarmaco SpA., Milan, Italy
-
S. Cazzaniga
4
Italfarmaco SpA., Milan, Italy
-
P. Bettica
4
Italfarmaco SpA., Milan, Italy
-
E. L. Finanger
5
Shriners Children's Portland, Portland, Oregon, United States
